$AIP

Alpern Paul L sold $36K of AIP

Alpern Paul L (VP and General Counsel) sold 998 shares of Arteris, Inc. (AIP) at $36.39 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Alpern Paul L
Published Jun 3, 2026, 9:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AIP
Neutral
medium confidence
Mentioned
$AIP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIPNeutralLow
01

Why it matters

The disclosure adds a concrete datapoint on insider activity but does not introduce new operating/financial information.

02

Market read

Primarily a sentiment/positioning datapoint; likely limited fundamental impact absent additional corroborating news.

03

What to watch

Traders may overreact to insider selling; the key is whether there are repeated consecutive sales or unusually large size versus prior filings (not provided here).

Relevance 6/10Novelty 6/10Timing: Filed June 3; sale executed June 1 (watch for any same-day/next-day sentiment drift).

Background

This is an SEC Form 4 insider transaction (officer/direct holdings) for Arteris, Inc., disclosed after the June 1 sale.

Company-level read

Ticker impact

$AIPNeutralMedium confidence
Context

Arteris’ VP & General Counsel sold 998 shares in an open-market transaction disclosed via SEC Form 4 on June 1 under a 10b5-1 plan.

Expected impact

Likely minimal; any reaction should be small and short-lived unless accompanied by other negative company-specific news.

Evidence & confidence

The filing is an ownership-change disclosure with a stated pre-arranged 10b5-1 plan, and the article provides no new fundamentals beyond the sale datapoint.

Market effects

No clear sector read-through from a single 10b5-1 insider sale disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine diversification/compensation rather than bearish expectations.

Key entities

  • Arteris, Inc.

    Subject of the SEC Form 4 insider transaction; VP & General Counsel sold shares under a 10b5-1 plan.

  • Alpern Paul L

    VP and General Counsel who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AIPMedAI 8/10

Arteris (AIP) Q2 2026 Earnings Call Transcript

Arteris, Inc. (AIP) reported Q2 2026 revenue of $24.1 million, up 46% year over year. ACV plus royalties were $99.5 million, up 44%, and remaining performance obligation was $135 million, up 36%. Cash and investments rose to $123 million after an at-the-market raise. Full-year 2026 revenue guidance was raised to $95-$98 million.

MedAI 8/10

Arteris Inc. raises FY26 sales guidance to $95-98M range

Arteris Inc. raised its FY2026 revenue guidance to $95.0 million to $98.0 million, up from $91.0 million to $95.0 million previously. The new range is above the $94.578 million analyst consensus estimate, reflecting stronger-than-expected demand for its NoC interconnects and design automation tools, according to the company.

$AIPHighAI 9/10

Arteris, Inc. (AIP): Results of Operations and Financial Condition

Arteris, Inc. (AIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2026 Guidance CAMPBELL, Calif. - August 6, 2026 - Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, to